Treatment of triple negative breast cancer and impact on patient survival

Authors

Ana Victória Mota Lima Centro Universitário Doutor Leão Sampaio, Juazeiro do Norte https://orcid.org/0000-0001-9323-6319
Wenderson Pinheiro de Lima Centro Universitário Doutor Leão Sampaio, Juazeiro do Norte https://orcid.org/0000-0003-4460-9830

Keywords:

Triple-negative neoplasia, Antineoplastics, Immunohistochemistry

Abstract

Describe the therapeutic options available and analyze the life expectancy of women diagnosed with triple-negative breast cancer. This was a systematic literature review, the search platforms LILACS, BVS, PubMed and Periódicos capes were used to find articles published from 2015 to 2021 in Portuguese, English and Spanish languages. The keywords "triple negative breast cancer" and "life expectancy" were applied, using the Boolean operator AND. In the end 14 studies were selected that fit the inclusion criteria. Triple-negative breast cancer has limited therapeutic options due to its immunohistochemical classification, thus being constantly subjected to chemotherapy, radiotherapy and surgical procedures that leave the patient weakened. However, other methodologies such as immunotherapy and the use of drugs with different therapeutic targets are under development, preliminary results show an increase in patient survival and the possibility of a promising future in the therapy of triple negative tumor.

Downloads

Download data is not yet available.

References

LOPES, C.M. et al. Fatores prognósticos clínicos, histomorfológicos e terapêuticos em pacientes com câncer de mama invasivo triplo-negativo. Jornal Brasileiro de Patologia e Medicina Laboratorial. v.15, n.6, p.397-406. 2015.

MASILI-OKU, S.M. et al. The Apocrine Profile of Triple-negative Breast Carcinomas in Patients Aged 45 Years or Younger: favorable but rare features. Revista Brasileira de Ginecologia e Obstetrícia. v.38, n.10, p.512-517. 2016.

INSTITUTO ONCOGUIA. Quimioterapia para câncer de mama. 2020. Disponível em: http://www.oncoguia.org.br/conteudo/quimioterapia-para-cancer-de-mama/1405/265/. Acesso em: 28 de março, 2021.

TAVARES, D.F. et al. O Estado da Arte da Imunoterapia no Tratamento do Câncer de Mama Triplo-Negativo: Principais drogas, associações, mecanismos de ação e perspectivas futuras. Revista Brasileira de Cancerologia. v.67, n.2. 2021.

COELHO, R.C.F.P. et al. Tratamento quimioterápico adjuvante e neoadjuvante e as implicações na qualidade de vida de mulheres com câncer de mama. Revista de enfermagem UFPE online. v.11, n.11, p.4732-4740. 2017.

KOZAKIEWICZ, A. M.B. et al. Clinicopathological factors associated with novel prognostic markers for patients with triple negative breast cancer. Clinical research oncology. v.15; n.6; p.1433-1442. 2018.

RAPITI, E. et al. Opportunities for improving triple-negative breast cancer outcomes: results of a population-based study. Cancer medicine. V.6; n.3; p.526-536. 2016

SCHMID, P. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. v.22; n.1; p. 1-16. 2019

DONG, P. et al. Identification of Key Genes and Pathways in Triple-Negative Breast Cancer by Integrated Bioinformatics Analysi. BioMed Research International. V. 2018; p.1-10. 2018.

DING, M. et al. Integrated Molecular Profiling of Young and Elderly Patients With Triple-Negative Breast Cancer Indicates Different Biological Bases and Clinical Management Strategies. Wiley Online Library. v. 126; n. 14; p.3209-3218. 2020

SHAGISULTANOVA, E., MAYORDOMO, J., ELIAS, A.D. Triple-negative breast cancer in the elderly. Wiley the breast journal. v. 23; n.6; p.627-629. 2017.

CURIGLIANO, G., PRAVETTONI, G. Use of chemotherapy in elderly patients with early-stage triple-negative breast câncer. The Lancet oncology. v. 21; p.1543-1545. 2020.

NAGATA, T. et al. KLF4 and NANOG are prognostic biomarkers for triple-negative breast cancer. The Japanese Breast Cancer Society. V.24; n.2; p.326-335. 2016.

KALSCHEUER, S. et al. Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer. Nature research. V.9; n.1; p.1-12. 2019.

BLUEM, J. L. et al. A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast câncer. Breast Cancer Res Treat. V.152; n.2; p.295-302. 2016.

LI, Y. et al. Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer. Scientific reports. v. 9; n.1; p.1-8. 2019.

Downloads

PDF (Português (Portugal))

Published

2022-11-09

How to Cite

Victória Mota Lima A, Pinheiro de Lima W. Treatment of triple negative breast cancer and impact on patient survival . Onco.News [Internet]. 2022 Nov. 9 [cited 2024 Nov. 21];(45):e054. Available from: https://onco.news/index.php/journal/article/view/54